Novel biomarkers demonstrated equal predictive value in determining all-cause mortality and composite outcomes when compared to established risk factors for chronic kidney disease (CKD), according to an article published this past June in the Journal of the American Society of Nephrology . The investigation into novel biomarkers was an effort to have a better mechanistic insight into CKD progression such that the data can then be used to support more personalized approaches to CKD care, such as personalized medicine and novel drug development.

Led by primary author Anthony Onoja , Ph.D., Faculty of Health and Medical Sciences, School of Health Sciences, University of Surrey, Guildford, United Kingdom, his team collected data from 2,884 participants enrolled in the UK-based National

See Full Page